GURU.Markets stock price, segment price, and overall market index valuation
The company's share price VolitionRx Limited
VolitionRx develops diagnostic tests for cancer detection using blood tests. Its stock price is a bet on the success of its Nu.Q technology. The stock price reflects high volatility and dependence on news about clinical data and commercialization.
Share prices of companies in the market segment - Cancer analysis
VolitionRx has developed the Nu.Q® blood testing platform, which can be used for the early detection of cancer and other diseases by detecting epigenetic markers in the bloodstream. We've categorized it under the "Cancer Analysis" segment. The graph below shows the overall dynamics of the liquid biopsy industry, which promises to make cancer diagnosis simple and accessible.
Broad Market Index - GURU.Markets
VolitionRx is a company developing simple blood tests for early detection of cancer and other diseases. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how VolitionRx compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
VNRX - Daily change in the company's share price VolitionRx Limited
The daily price change of VolitionRx Limited, a developer of cancer diagnostic tests, reflects volatility in the MedTech sector. This indicator demonstrates sensitivity to news about clinical validation and commercialization, making it an important element of analysis.
Daily change in the price of a set of shares in a market segment - Cancer analysis
VolitionRx Limited is a cancer diagnostics company. This chart highlights the high volatility of the healthcare sector. Comparison with the performance of VNRX, which focuses on testing, helps us understand it as an innovative player whose volatility is driven by clinical data.
Daily change in the price of a broad market stock, index - GURU.Markets
VolitionRx Limited is developing simple blood tests for early-stage cancer detection. This is the holy grail of oncology. The company's success could transform medicine. Its stock price fluctuates, reflecting both enormous hopes and scientific risks, and this dramatic momentum is part of the overall market volatility you see on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization VolitionRx Limited
For VolitionRx Limited, the year-over-year performance is a story of commercialization of its blood-based cancer early detection tests (Nu.Q). Its market capitalization growth over the past 12 months reflects its success in securing contracts for the use of its tests in veterinary medicine, as well as progress in clinical trials for human use.
Annual dynamics of market capitalization of the market segment - Cancer analysis
VolitionRx Limited develops simple blood tests for early cancer detection. Its technology is targeting a massive market. The chart shows how its scientific advancements, commercialization progress, and competition in this rapidly evolving field are impacting its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
VolitionRx, which develops tests for early cancer detection, is a growth story in healthcare. Its stock price is driven not by the economy, but by demand for its innovative tests. The chart illustrates how a breakthrough technology can create and capture a new multi-billion dollar market, regardless of the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization VolitionRx Limited
VolitionRx develops diagnostic tests for the early detection of cancer. Its monthly performance reflects progress in the commercialization of its Nu.Q tests. News of regulatory approvals, laboratory partnerships, and clinical trial data are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
VolitionRx is developing simple blood tests for early-stage cancer diagnosis based on nucleosome analysis. This is a promising but competitive field. The company's success depends on the accuracy of its tests and their implementation in clinical practice. The dynamics of the medical diagnostics sector reflect the general interest in "liquid biopsy," which forms the backdrop for VolitionRx's valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
VolitionRx is developing blood-based tests for early cancer detection. This is a breakthrough, but high-risk, field. The company's stock price is entirely dependent on the success of its technology and clinical validation data. Its market correlation is minimal, and the chart reflects investor hopes for a revolution in cancer diagnostics.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization VolitionRx Limited
The weekly performance of VolitionRx, which develops blood-based tests for early cancer detection, reflects expectations for a breakthrough in this field. News of their test validation, partnerships with major laboratories, and publications in scientific journals are generating strong investor reactions.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
VolitionRx and the entire liquid biopsy industry are moving against a backdrop of scientific breakthroughs and expectations. Regulatory announcements and clinical trial data are creating significant volatility for everyone. This chart shows how the company stacks up against this innovative backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
VolitionRx and the entire liquid biopsy industry are moving against a backdrop of scientific breakthroughs and expectations. Regulatory announcements and clinical trial data are creating significant volatility for everyone. This chart shows how the company stacks up against this innovative backdrop.
Market capitalization of the company, segment and market as a whole
VNRX - Market capitalization of the company VolitionRx Limited
VolitionRx's market cap is the financial valuation of a company developing simple blood tests for early cancer detection. The chart reflects investor hopes for its Nu.Q platform. Its dynamics are a story of the balance between a huge potential market and intense competition, where every positive research result can spark a surge of interest.
VNRX - Share of the company's market capitalization VolitionRx Limited within the market segment - Cancer analysis
VolitionRx develops simple blood tests for the early detection of cancer and other diseases. The company's market share reflects its pioneering status in the fields of liquid biopsy and epigenetics. The chart below shows the market share of its technology, which could revolutionize cancer screening.
Market capitalization of the market segment - Cancer analysis
VolitionRx is developing simple blood tests for cancer diagnostics. The chart below shows the total market capitalization of the entire oncology diagnostics sector. Its dynamics represent hope for early detection. At this cutting-edge scientific frontier, VolitionRx strives to make cancer diagnostics more accessible.
Market capitalization of all companies included in a broad market index - GURU.Markets
Early cancer detection is the holy grail of medicine, driving future valuations. VolitionRx is developing simple blood tests for early-stage cancer detection. Its valuation is a risky bet that its technology will become part of standard medical checkups.
Book value capitalization of the company, segment and market as a whole
VNRX - Book value capitalization of the company VolitionRx Limited
VolitionRx's book value is the material foundation for a revolution in cancer diagnostics. The chart reflects investments in R&D laboratories and manufacturing facilities to create unique Nu.Q blood tests. These physical assets enable the development of simple and affordable tests for early cancer detection.
VNRX - Share of the company's book capitalization VolitionRx Limited within the market segment - Cancer analysis
VolitionRx develops cancer diagnostic tests. Its stake in the sector includes its state-of-the-art laboratories and manufacturing facilities for creating diagnostic kits. This physical infrastructure forms the foundation for the commercialization of its innovative Nu.Q blood testing technology.
Market segment balance sheet capitalization - Cancer analysis
VolitionRx Limited develops diagnostic tests, making its business less capital-intensive than drug manufacturers. It doesn't require large manufacturing facilities, but it does require certified laboratories and R&D centers. Compared to the healthcare sector, its model focuses on intellectual property and a technology platform.
Book value of all companies included in the broad market index - GURU.Markets
VolitionRx's assets are not drugs, but rather the cutting-edge Nu.Q blood testing technology, capable of detecting cancer at early stages. The company's balance sheet reflects the value of this unique diagnostic platform. The chart shows the capital invested in developing a "liquid biopsy" that could save millions of lives.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - VolitionRx Limited
VolitionRx develops tests for early cancer detection. Its market value exceeds its book value by many times, as investors are paying for its unique Nu.Q. technology and its enormous market potential. The chart shows how the market views its chances of revolutionizing cancer diagnostics.
Market to book capitalization ratio in a market segment - Cancer analysis
VolitionRx develops diagnostic tests for early cancer detection. The company's value lies in its scientific platform and patents. This chart shows how much its market valuation, based on the potential of its technology to transform medicine, exceeds the cost of its lab equipment and reagents.
Market to book capitalization ratio for the market as a whole
VolitionRx develops blood-based tests for early cancer detection. The company's value lies in its unique technology and patents, not in its lab equipment. The chart clearly demonstrates the enormous premium the market is paying for the potential of this technology to revolutionize medicine and save millions of lives.
Debts of the company, segment and market as a whole
VNRX - Company debts VolitionRx Limited
VolitionRx develops blood-based cancer diagnostic tests. Commercializing such innovative products requires significant investment in research, validation studies, and marketing. Debt financing can serve as a tool to accelerate the market launch of these vital tests.
Market segment debts - Cancer analysis
VolitionRx Limited develops diagnostic tests for the early detection of cancer. In the medical diagnostics sector, R&D and commercialization require significant resources. This chart shows how the company is funding this: through equity, which is typical in the industry, or through debt, which may indicate that the products are approaching market maturity and stable revenues are expected.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio VolitionRx Limited
VolitionRx develops cancer diagnostic tests, which requires significant investments in research and development and regulatory approvals. This chart shows the company's debt load. While debt accelerates the product's time to market, if the technology isn't approved or accepted by the medical community, the debt could become a critical issue.
Market segment debt to market segment book capitalization - Cancer analysis
VolitionRx is developing simple blood tests for early-stage cancer detection. The company's technology has the potential to revolutionize cancer screening. This chart compares the debt raised for R&D and commercialization to the total market capitalization of the entire cancer testing sector. It reflects the financial stakes associated with creating a breakthrough diagnostic platform.
Debt to book value of all companies in the market
VolitionRx, a developer of cancer diagnostic tests, is in the active research and commercialization phase. The chart below illustrates its approach to financing: whether the company relies on equity or debt. This is critical for assessing risk in biotech, where market leverage often reflects investors' confidence in future success.
P/E of the company, segment and market as a whole
P/E - VolitionRx Limited
This chart for VolitionRx, which develops tests for early cancer detection, is an assessment of its revolutionary potential. The high price per dollar of future revenue reflects the enormous hope that its technology will transform medicine. The price per dollar reflects the market's reaction not to current sales, but to news about the accuracy of the tests and their clinical adoption.
P/E of the market segment - Cancer analysis
This chart shows the average valuation for the biotech diagnostics sector—the benchmark for VolitionRx. The industry's high valuation reflects the belief that early cancer detection will transform medicine. Comparing this metric helps us understand whether investors consider VolitionRx's technology to be among the most promising in this race.
P/E of the market as a whole
VolitionRx is developing simple blood tests for early-stage cancer detection. The company's technology could revolutionize approaches to oncology by making screening widespread and accessible. This chart demonstrates the market's overall propensity to support long-term innovations. It helps determine whether VolitionRx is supported by general optimism or whether its technology is a game-changer in its own right.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company VolitionRx Limited
VolitionRx is developing simple blood tests for early-stage cancer detection. The company's future profitability depends on the commercialization of its tests and their acceptance by the medical community. This chart shows whether analysts believe Nu.Q's technology can become a standard in cancer diagnostics and generate stable revenue.
%20P%2FE%20VolitionRx%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-VolitionRx-Limited&v=1772617215892 "Chart of the company's future (projected) P/E VolitionRx Limited")
Future (projected) P/E of the market segment - Cancer analysis
VolitionRx develops easy-to-use blood tests for early-stage cancer detection using its Nu.Q technology. This chart compares the company's future profitability expectations with the diagnostics sector, demonstrating the extent to which investors believe its technology can become the new standard in cancer screening.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772617215899 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
VolitionRx is developing simple blood tests for cancer diagnostics. This chart reflects the overall investment climate. For VolitionRx, as a medical diagnostics company, the speed of acceptance of their tests by the medical community is more important than the economics. Successful results and approvals will generate demand regardless of market sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772617215931 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit VolitionRx Limited
VolitionRx develops simple blood tests for cancer diagnosis. The company aims to make early cancer detection more accessible. This chart illustrates the financial side of medical innovation. The results reflect the investment in research and clinical trials necessary to obtain regulatory approval and bring the tests to market.
Profit of companies in the market segment - Cancer analysis
VolitionRx is developing simple and affordable blood tests for early cancer detection based on its Nu.Q technology. Early detection is a key goal of modern medicine. This chart shows the financial pulse of the oncology diagnostics sector, reflecting the market's willingness to accept and pay for new, more effective screening methods.
Overall market profit
VolitionRx develops simple and affordable blood tests for diagnosing cancer and other diseases. The company's technology is based on the analysis of nucleosomes in blood. VolitionRx's success depends on clinical validation and the implementation of its tests in medical practice, which could revolutionize early diagnosis.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company VolitionRx Limited
VolitionRx is developing simple blood tests for early cancer detection. This is a revolutionary approach to medicine. The profit forecast presented here is a model based on analysts' expectations for the widespread adoption of its tests by the medical community and insurance coverage, which will determine future revenue.
%20profit%20of%20the%20company%20VolitionRx%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-VolitionRx-Limited&v=1772617216038 "Graph of future (projected) profit of the company VolitionRx Limited")
Future (predicted) profit of companies in the market segment - Cancer analysis
VolitionRx is developing breakthrough blood tests for early cancer detection, one of the most pressing challenges in modern medicine. This chart reflects the high expectations for the oncology diagnostics sector. VolitionRx's success in creating accessible and accurate tests could not only dramatically change its financial performance but also impact the profitability of the entire industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772617216096 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
VolitionRx is developing blood-based tests for early cancer detection. Implementing new diagnostic methods requires significant investment from healthcare systems, which are dependent on economic performance. This graph, illustrating corporate profit projections, helps assess how favorable the financial environment will be for innovative medical solutions.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772617216163 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - VolitionRx Limited
VolitionRx is developing simple blood tests for cancer diagnosis. This chart shows how highly investors value the potential of its technology, despite its modest current revenue. It reflects the hopes that its tests will become the standard for early cancer diagnosis and capture a huge market.
P/S market segment - Cancer analysis
VolitionRx is developing simple and affordable blood tests for early-stage cancer diagnosis based on its Nu.Q platform. Revenue growth will depend on the commercialization and adoption of these tests in clinical practice. This chart shows the average valuation in the diagnostics sector, helping to understand the market premium placed on the revolutionary potential of VolitionRx's technology.
P/S of the market as a whole
VolitionRx is developing simple blood tests for early-stage cancer diagnosis. This is a breakthrough technology in oncology. The company's revenue is still small, but its potential is enormous. This market valuation chart helps us understand the enormous premium investors are pricing in for the company's revolutionary potential in medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company VolitionRx Limited
VolitionRx is developing simple and affordable blood tests for early cancer detection based on its Nu.Q platform. This chart reflects investors' confidence in the future commercial success of these tests. The valuation is based on expected revenues from the widespread adoption of its diagnostic products in clinical practice worldwide.
%20P%2FS%20VolitionRx%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-VolitionRx-Limited&v=1772617216274 "The graph of the company's future (projected) P/S VolitionRx Limited")
Future (projected) P/S of the market segment - Cancer analysis
VolitionRx is developing simple blood tests for early cancer detection. This chart compares the company's future revenue expectations with its industry. It reflects the market's assessment of the revolutionary potential of Nu.Q's technology and investors' belief that it will become the standard in cancer screening.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772617216298 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
VolitionRx is developing easy-to-use blood tests for early-stage cancer detection. This chart shows overall revenue expectations, and VolitionRx is a prime example of where they are coming from. Success with its Nu.Q technology could revolutionize oncology, save millions of lives, and create a new multibillion-dollar market in diagnostics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772617216370 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales VolitionRx Limited
VolitionRx develops and commercializes easy-to-use blood tests for cancer diagnostics. Revenue, shown in this chart, is generated from sales of these diagnostic tests, primarily for the veterinary market, as well as from research contracts. Growth reflects the adoption of its technology in clinical practice.
Sales of companies in the market segment - Cancer analysis
VolitionRx is developing simple and affordable blood tests for early cancer detection. Their Nu.Q technology has the potential to revolutionize cancer screening, bringing it to the masses. This chart shows revenue in the diagnostics sector, where such breakthrough tests have the potential to radically change the market structure and save millions of lives.
Overall market sales
VolitionRx Limited is developing blood-based tests for early cancer detection. The implementation of such innovations depends on healthcare system budgets. The increase in overall economic revenue, reflected in the graph, means improved funding for clinics and laboratories. This accelerates the adoption of new, more effective diagnostic methods offered by VolitionRx.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company VolitionRx Limited
VolitionRx Limited develops simple and affordable blood tests for the early detection of cancer and other diseases. The company's Nu.Q technology is capable of detecting cancer at an early stage. This graph shows analysts' expectations for the commercialization of these tests and their widespread adoption for population screening.
%20sales%20of%20the%20company%20VolitionRx%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-VolitionRx-Limited&v=1772617216736 "Schedule of future (projected) sales of the company VolitionRx Limited")
Future (projected) sales of companies in the market segment - Cancer analysis
VolitionRx develops easy-to-use and affordable blood tests for early-stage cancer detection. Nu.Q technology is designed to revolutionize cancer diagnostics. This chart shows forecasts for the entire cancer testing sector, allowing us to estimate the potential contribution of this breakthrough technology to market growth.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772617216780 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
VolitionRx, which develops blood-based cancer diagnostic tests, sees this chart as an indicator of investment in preventive medicine. The economic growth projected here allows healthcare systems and insurance companies to invest more in early detection, expanding the market for VolitionRx's innovative and affordable tests.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772617216813 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality VolitionRx Limited
VolitionRx is developing innovative blood tests for early cancer detection. As the tests reach the market, profitability will depend on their acceptance by the medical community and the cost of testing. This chart shows how successfully the company is moving from R&D to commercialization, converting revenue from its Nu.Q technology into profit.
Market segment marginality - Cancer analysis
VolitionRx is developing simple blood tests for cancer diagnostics. In the medtech sector, where research costs are high, operational efficiency is critical. The data demonstrates how successfully the company has managed costs during the commercialization of its Nu.Q technology compared to other diagnostic companies seeking to transform medicine.
Market marginality as a whole
VolitionRx is developing simple blood tests for cancer diagnostics, aiming to make early detection accessible. Based on its overall profitability, VolitionRx is operating in the field of breakthrough diagnostics. Their future profitability depends on the accuracy of their tests, regulatory approval, and widespread adoption in medical practice.
Employees in the company, segment and market as a whole
Number of employees in the company VolitionRx Limited
VolitionRx develops breakthrough blood tests for early cancer detection. The company's team, whose scale is evident in this chart, includes scientists, lab technicians, and commercialization specialists. The growth of its staff is an indicator of progress in research and the approach to bringing life-saving diagnostic products to market.
Share of the company's employees VolitionRx Limited within the market segment - Cancer analysis
VolitionRx is developing simple blood tests for early cancer detection. In this cutting-edge field, its key asset is the best minds in biochemistry and oncology. The data presented shows the company's share of all scientists and technicians in the oncology diagnostics sector, a measure of its innovative potential and the scale of its research platform.
Number of employees in the market segment - Cancer analysis
VolitionRx is developing simple blood tests for cancer diagnostics. Its main asset is its team of scientists and technicians. This chart illustrates how the company is expanding its research and commercial capabilities. Headcount growth, particularly in the sales and marketing departments, may signal preparations for product launches or expansion of their applications.
Number of employees in the market as a whole
VolitionRx develops tests for early cancer detection. The healthcare sector, and oncology in particular, is one of the most resilient to economic downturns. This graph reflects the overall picture, but the need for innovative diagnostic methods drives companies like VolitionRx to hire top scientists regardless of economic downturns.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company VolitionRx Limited (VNRX)
VolitionRx develops innovative cancer diagnostic tests. For such companies, this metric reflects the value of their technology. A high value on the chart means the market is pricing in the life-saving potential and future cash flows from sales of tests developed by a small team.
%20of%20the%20company%20VolitionRx%20Limited%20(VNRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-VolitionRx-Limited-VNRX&v=1772617217300 "Chart of market capitalization per employee (in thousands of dollars) of the company VolitionRx Limited (VNRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
VolitionRx develops easy-to-use blood tests for cancer diagnostics. The company's value lies in its unique Nu.Q technology. This metric demonstrates the market value generated by each employee working on this breakthrough technology. A comparison with the industry will reveal whether the market sees their approach as more valuable.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772617217361 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
VolitionRx develops simple blood tests for early-stage cancer detection. The company's value lies in its unique Nu.Q technology. This chart illustrates how the market appreciates the potential of a breakthrough diagnostic platform, where the intellectual contribution of a small scientific team can transform approaches to cancer screening.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772617217389 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company VolitionRx Limited (VNRX)
VolitionRx develops diagnostic tests (blood tests) for the early detection of cancer. This is the diagnostics sector. This graph shows how effectively the company is progressing toward commercialization. While the tests are in development, the indicator is negative (R&D costs). Upon market launch, this indicator will show how profitable their technology is per employee.
%20Chart%20VolitionRx%20Limited%20(VNRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-VolitionRx-Limited-VNRX&v=1772617217403 "Company Profit Per Employee (in thousands of dollars) Chart VolitionRx Limited (VNRX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
VolitionRx (VNRX) specializes in the development and commercialization of diagnostic tests (blood tests) for early cancer detection. For a company in the diagnostics sector, this metric reflects the effectiveness of the transition from research to sales. It demonstrates how successfully the team (scientists, marketers, and lab technicians) transforms scientific research into a commercial, revenue-generating product.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772617217476 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
VolitionRx develops tests for early cancer detection. It's a high-tech business in the life sciences sector, where intellectual capital is valued more than physical capital. This chart shows how effectively the company monetizes its scientific research. At the R&D stage, the indicator is negative, but if successful and the tests are widely adopted, the profit per employee could become astronomical due to the low cost of the tests themselves.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772617217479 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee VolitionRx Limited (VNRX)
VolitionRx is developing simple blood tests for cancer diagnostics. This graph illustrates how scientific innovations can be transformed into a commercial product. Increasing revenue per employee will mean their tests become more widely used in medical practice, and their small team can effectively scale sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-VolitionRx-Limited-VNRX&v=1772617217494 "Sales chart per company employee VolitionRx Limited (VNRX)")
Sales per employee in the market segment - Cancer analysis
VolitionRx develops blood-based tests for early cancer detection (Nu.Q technology). In the diagnostics sector, the efficiency of R&D and commercialization is crucial. This chart shows the average revenue per employee in the industry. It helps evaluate how productive the VolitionRx team is in bringing its innovative tests to market compared to other diagnostics companies.
Sales per employee for the market as a whole
VolitionRx Limited develops simple blood tests (Nu.Q tests) for early-stage cancer diagnosis. It operates in the liquid biopsy space. This chart shows how effectively the company is commercializing its tests. Growth here will mean successful clinical adoption and scaling revenue per employee.
Short shares by company, segment and market as a whole
Shares shorted by company VolitionRx Limited (VNRX)
VolitionRx is developing simple blood tests (Nu.Q technology) for early cancer detection in humans and animals. This is the "holy grail" of diagnostics, but it faces enormous scientific hurdles. The chart reflects investor skepticism: they are betting that the technology won't prove accurate in clinical trials or that the company won't be able to commercialize its tests.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-VolitionRx-Limited-VNRX&v=1772617217660 "Short Shares Chart for the Company VolitionRx Limited (VNRX)")
Shares shorted by market segment - Cancer analysis
VolitionRx is developing simple blood tests (Nu.Q) for early cancer detection. This is a promising but complex field. This chart illustrates the overall pessimism in the sector. If the price rises, investors doubt that new diagnostic tests will be widely adopted or reimbursed by insurers, which is holding back the entire industry.
Shares shorted by the overall market
VolitionRx is developing tests for early cancer detection. It's a promising industry. But this chart reflects overall market pessimism. At times like these, investors may overlook scientific potential if the company is still spending more than it earns. Fear drives the market to demand immediate profitability.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator VolitionRx Limited (VNRX)
This chart shows the market reaction to VolitionRx's progress in liquid biopsy. The company is developing Nu.Q blood tests for early cancer detection, one of the hottest topics in medicine. The publication of strong test validation data or regulatory approval triggers a surge in optimism, pushing the oscillator above 70. Delays or mixed trial results lead to a sharp cooldown (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-VolitionRx-Limited-VNRX&v=1772617217769 "RSI 14 indicator chart for the company's stock VolitionRx Limited (VNRX)")
RSI 14 Market Segment - Cancer analysis
VolitionRx (VNRX) is "liquid biopsy" 2.0. Their *blood tests* (Nu.Q) look for *not* cancer DNA, but *"fingerprints"* (epigenetics) of cancer on *nucleosomes*. The "Cancer Analysis" sector (biotech/diagnostics) thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is VNRX's growth a niche or a general hype?
RSI 14 for the overall market
VolitionRx (VNRX) develops cancer diagnostic tests. This chart is its lifeline. Its business is pure R&D. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and VNRX risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VNRX (VolitionRx Limited)
VolitionRx is developing the Nu.Q platform—simple blood tests for early cancer detection. The company also has a veterinary division (Nu.Q Vet). This chart shows the speculative average price target from analysts, based on their belief in the commercialization of this diagnostic technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VNRX-VolitionRx-Limited&v=1772617217957 "A chart showing analyst consensus forecasts for the expected stock price. VNRX (VolitionRx Limited)")
The difference between the consensus estimate and the actual stock price VNRX (VolitionRx Limited)
VolitionRx (VNRX) is a diagnostic company developing a "liquid biopsy" (Nu.Q test) for early cancer detection using blood tests. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their screening technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VNRX-VolitionRx-Limited&v=1772617218010 "A chart showing the difference between the consensus forecast and the actual stock price. VNRX (VolitionRx Limited)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
VolitionRx (VNRX) is a diagnostic company developing blood-based tests (Nu.Q) for the early detection of cancer. This chart shows analysts' overall expectations for the oncology testing sector. It reflects whether experts believe in the "liquid biopsy" boom and the company's ability to compete in this market.
Analysts' consensus forecast for the overall market share price
VolitionRx (VNRX) is a company specializing in liquid biopsy. They are developing blood tests (Nu.Q) that help diagnose cancer early by analyzing DNA fingerprints. This chart shows overall market sentiment. For Volition, which operates in the defensive healthcare sector, overall optimism is important, but their growth is more dependent on the acceptance of their tests by insurance companies and doctors.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index VolitionRx Limited
VolitionRx is a cancer hunter. They're developing simple blood tests (Nu.Q) that aim to act as an alarm system—they measure DNA fragments (nucleosomes) to aid in early cancer detection. This graph summarizes their R&D journey, reflecting their slow but steady progress in clinical trials and their struggle for commercialization (especially in veterinary medicine).
AKIMA Market Segment Index - Cancer analysis
VolitionRx Limited (VNRX) develops simple blood tests (based on Nu.Q technology) for diagnosing cancer and other diseases. Their goal is early and affordable diagnosis. The chart shows the average index for the segment. It helps investors assess how successfully VolitionRx is advancing its diagnostic platform compared to the oncology testing sector average.
The AKIM Index for the overall market
VolitionRx is a diagnostic company developing simple blood tests (Nu.Q) to detect cancer and other diseases in humans and animals. This chart, which reflects the market average, provides context. It helps assess how this innovative epigenetics platform compares to overall macroeconomic trends.
